DuChemBIO Co.,Ltd. (176750.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
6,070.00 KRW
Market cap
172.05 bn KRW
P/E (2025)
26.55
P/S (2025)
4.46
Dividend yield
0.00 %
Net margin
16.80 %
Return on equity (ROE)
13.16 %
Return on assets (ROA)
8.34 %

DuChemBIO Co.,Ltd. financials

Fiscal year20242025
Revenue35.60 bn KRW38.57 bn KRW
Gross profit12.23 bn KRW14.23 bn KRW
Operating income5.08 bn KRW7.44 bn KRW
EBIT6.66 bn KRW7.72 bn KRW
Net income7.99 bn KRW6.48 bn KRW
Diluted EPS – continuing operations282.02 KRW228.61 KRW

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About DuChemBIO Co.,Ltd.

DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.